JP2009529576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009529576A5 JP2009529576A5 JP2009500402A JP2009500402A JP2009529576A5 JP 2009529576 A5 JP2009529576 A5 JP 2009529576A5 JP 2009500402 A JP2009500402 A JP 2009500402A JP 2009500402 A JP2009500402 A JP 2009500402A JP 2009529576 A5 JP2009529576 A5 JP 2009529576A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- virus
- composition according
- highly conserved
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004414 DNA Proteins 0.000 claims description 39
- 241000700605 Viruses Species 0.000 claims description 30
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 239000013612 plasmid Substances 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 230000005867 T cell response Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 40
- 102000053602 DNA Human genes 0.000 claims 17
- 108700005077 Viral Genes Proteins 0.000 claims 16
- 230000002238 attenuated effect Effects 0.000 claims 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 4
- 230000002779 inactivation Effects 0.000 claims 4
- 208000032420 Latent Infection Diseases 0.000 claims 3
- 241001631646 Papillomaviridae Species 0.000 claims 3
- 208000037581 Persistent Infection Diseases 0.000 claims 3
- 101150009795 UL54 gene Proteins 0.000 claims 3
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 231100000283 hepatitis Toxicity 0.000 claims 3
- 241001529453 unidentified herpesvirus Species 0.000 claims 3
- 241001430294 unidentified retrovirus Species 0.000 claims 3
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 21
- 241000710118 Maize chlorotic mottle virus Species 0.000 description 14
- 230000003053 immunization Effects 0.000 description 13
- 238000002649 immunization Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 210000004988 splenocyte Anatomy 0.000 description 10
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 3
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 102000016559 DNA Primase Human genes 0.000 description 2
- 108010092681 DNA Primase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
Images
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78112306P | 2006-03-10 | 2006-03-10 | |
| PCT/US2007/006113 WO2007106404A2 (en) | 2006-03-10 | 2007-03-09 | Vaccine for viruses that cause persistent or latent infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009529576A JP2009529576A (ja) | 2009-08-20 |
| JP2009529576A5 true JP2009529576A5 (enExample) | 2010-04-30 |
Family
ID=38510006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500402A Pending JP2009529576A (ja) | 2006-03-10 | 2007-03-09 | 持続感染または潜伏感染を引き起こすウイルスに対するワクチン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8501194B2 (enExample) |
| EP (1) | EP2001516A4 (enExample) |
| JP (1) | JP2009529576A (enExample) |
| CA (1) | CA2645507A1 (enExample) |
| WO (1) | WO2007106404A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2203184B1 (en) * | 2007-09-21 | 2012-03-14 | Sanofi Pasteur | Vaccine composition for the prevention of cmv infections |
| ES2732815T3 (es) | 2009-05-22 | 2019-11-26 | Genocea Biosciences Inc | Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria |
| US8979890B2 (en) | 2010-10-01 | 2015-03-17 | Ethicon Endo-Surgery, Inc. | Surgical instrument with jaw member |
| EP2643014A4 (en) | 2010-11-24 | 2015-11-11 | Genocea Biosciences Inc | HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE |
| AU2012212264B2 (en) * | 2011-01-31 | 2016-01-28 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
| JP6109165B2 (ja) * | 2011-07-01 | 2017-04-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ヘルペスウイルスワクチンおよび使用方法 |
| EP2766385A2 (en) * | 2011-10-12 | 2014-08-20 | Novartis AG | Cmv antigens and uses thereof |
| JP6199878B2 (ja) | 2011-11-23 | 2017-09-20 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法 |
| ES2765880T3 (es) | 2012-01-09 | 2020-06-11 | Sanofi Pasteur Biologics Llc | Purificación del virus del herpes |
| WO2013177172A2 (en) | 2012-05-21 | 2013-11-28 | Sanofi Pasteur Limited | Herpesvirus compositions and related methods |
| WO2014005643A1 (en) * | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
| WO2014089158A1 (en) * | 2012-12-04 | 2014-06-12 | Merck Sharp & Dohme Corp. | Conditional replicating viral vectors |
| EP3888676A1 (en) | 2014-06-13 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
| US10314383B2 (en) | 2015-03-30 | 2019-06-11 | Gary McClellan Thompson | Wearable sports equipment carrier with personal flotation device |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| WO2018064232A1 (en) | 2016-09-28 | 2018-04-05 | Genocea Biosciences, Inc. | Methods and compositions for treating herpes |
| WO2019044927A1 (ja) * | 2017-08-30 | 2019-03-07 | Ｋｍバイオロジクス株式会社 | 改変型ＨＳＶ ｇＢタンパク質及びこれを含むＨＳＶワクチン |
| WO2020016433A1 (en) * | 2018-07-20 | 2020-01-23 | Aicuris Gmbh & Co. Kg | Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| EP4147712A1 (en) * | 2021-09-13 | 2023-03-15 | OncoDNA | Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient |
| CA3230564A1 (en) * | 2021-09-13 | 2023-03-16 | Jean-Pol DETIFFE | Method to generate personalized neoantigens of a tumor of a patient |
-
2007
- 2007-03-09 EP EP07752789A patent/EP2001516A4/en not_active Withdrawn
- 2007-03-09 US US12/282,123 patent/US8501194B2/en not_active Expired - Fee Related
- 2007-03-09 CA CA 2645507 patent/CA2645507A1/en not_active Abandoned
- 2007-03-09 WO PCT/US2007/006113 patent/WO2007106404A2/en not_active Ceased
- 2007-03-09 JP JP2009500402A patent/JP2009529576A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009529576A5 (enExample) | ||
| Del Val et al. | Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89 | |
| CN112618707B (zh) | 一种SARS-CoV-2冠状病毒疫苗及其制备方法 | |
| Ghiasi et al. | Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice | |
| CN113666990B (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
| JP7579245B2 (ja) | 組成物及び方法 | |
| KR101702956B1 (ko) | 다수의 상동성 뉴클레오티드 서열을 포함하는 벡터 | |
| CN113201507B (zh) | 一种重组的伪狂犬病病毒及其疫苗组合物 | |
| CN104271745A (zh) | 用于治疗巨细胞病毒的组合物和方法 | |
| Mitra-Kaushik et al. | Identification of a cytotoxic T-cell epitope on the recombinant nucleocapsid proteins of Rinderpest and Peste des petits ruminants viruses presented as assembled nucleocapsids | |
| PT2753364T (pt) | Citomegalovirus de replicação condicional como uma vacina para cmv | |
| SG175781A1 (en) | Recombinant virus-like particles encoded by multi-gene vector | |
| CN109415705A (zh) | 组合初免:加强免疫疗法 | |
| CN116457461A (zh) | 重组hvt及其用途 | |
| Stock et al. | CTL response compensation for the loss of an immunodominant class I‐restricted HSV‐1 determinant | |
| KR20230022206A (ko) | 코로나바이러스 질환에 대응하는 재조합적 변형된 우두증 바이러스 앙카라 (mva) 백신 | |
| CN111154778B (zh) | 禽新城疫病毒新型基因工程亚单位疫苗 | |
| CN115845042A (zh) | 重组新型冠状病毒s蛋白三聚体疫苗组合物及其应用 | |
| CN114276969A (zh) | 一种SARS-CoV-2细菌样颗粒及其在疫苗中的应用 | |
| EP1624890A2 (en) | Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes | |
| WO2023236822A1 (zh) | H5n6禽流感广谱性疫苗的开发及其应用 | |
| WO2023207717A1 (zh) | H5n8禽流感广谱性疫苗的开发及其应用 | |
| CN116549627A (zh) | 基于腺病毒载体的广谱新冠疫苗及其应用 | |
| WO2023092023A2 (en) | Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19) | |
| US20220257748A1 (en) | Hepatitis b virus-specific t cell responses |